• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腱鞘巨细胞瘤的发病率高于此前所知。

Higher incidence rates than previously known in tenosynovial giant cell tumors.

作者信息

Mastboom Monique J L, Verspoor Floortje G M, Verschoor Arjan J, Uittenbogaard Daniël, Nemeth Banne, Mastboom Walter J B, Bovée Judith V M G, Dijkstra P D Sander, Schreuder H W Bart, Gelderblom Hans, Van de Sande Michiel A J

机构信息

a Orthopedic Surgery , Leiden University Medical Center , Leiden.

b Orthopedic Surgery , Radboud University Medical Center , Nijmegen.

出版信息

Acta Orthop. 2017 Dec;88(6):688-694. doi: 10.1080/17453674.2017.1361126. Epub 2017 Aug 8.

DOI:10.1080/17453674.2017.1361126
PMID:28787222
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5694816/
Abstract

Background and purpose - Tenosynovial giant cell tumors (TGCT) are rare, benign tumors, arising in synovial lining of joints, tendon sheaths, or bursae. 2 types are distinguished: localized, either digits or extremity, and diffuse lesions. Current TGCT incidence is based on 1 single US-county study in 1980, with an incidence of 9 and 2 per million person-years in localized (including digits) and diffuse TGCT, respectively. We aim to determine nationwide and worldwide incidence rates (IR) in TGCT affecting digits, localized-extremity TGCT and diffuse-type TGCT. Material and methods - Over a 5-year period, the Dutch Pathology Registry (PALGA) identified 4,503 pathology reports on TGCT. Reports affecting digits were solely used for IR calculations. Reports affecting extremities were clinically evaluated. Dutch IRs were converted to world population IRs. Results - 2,815 (68%) digits, 933 (23%) localized-extremity and 390 (9%) diffuse-type TGCT were identified. Dutch IR in digits, localized-extremity, and diffuse-type TGCT was 34, 11 and 5 per million person-years, respectively. All 3 groups showed a female predilection and highest number of new cases in age category 40-59 years. The knee joint was most often affected: localized-extremity (46%) and diffuse-type (64%) TGCT, mostly treated with open resection: localized (65%) and diffuse (49%). Reoperation rate due to local recurrence for localized-extremity was 9%, and diffuse TGCT 23%. Interpretation - This first nationwide study and detailed analyses of IRs in TGCT estimated a worldwide IR in digits, localized-extremity and diffuse TGCT of 29, 10, and 4 per million person-years, respectively. Recurrence rate in diffuse type is 2.6 times higher, compared with localized extremity. TGCT is still considered a rare disease; however, it is more common than previously understood.

摘要

背景与目的——腱鞘巨细胞瘤(TGCT)是一种罕见的良性肿瘤,起源于关节、腱鞘或滑囊的滑膜衬里。可分为2种类型:局限性,累及手指或四肢,以及弥漫性病变。目前TGCT的发病率基于1980年美国一个县的单一研究,局限性(包括手指)和弥漫性TGCT的发病率分别为每百万人年9例和2例。我们旨在确定影响手指、局限性四肢TGCT和弥漫型TGCT的全国和全球发病率(IR)。材料与方法——在5年期间,荷兰病理登记处(PALGA)识别出4503份关于TGCT的病理报告。仅将影响手指的报告用于发病率计算。对影响四肢的报告进行临床评估。将荷兰的发病率转换为世界人口发病率。结果——共识别出2815例(68%)手指、933例(23%)局限性四肢和390例(9%)弥漫型TGCT。荷兰手指、局限性四肢和弥漫型TGCT的发病率分别为每百万人年34例、11例和5例。所有3组均表现出女性偏好,且40 - 59岁年龄组的新发病例数最多。膝关节最常受累:局限性四肢(46%)和弥漫型(64%)TGCT,大多采用开放切除治疗:局限性(65%)和弥漫性(49%)。局限性四肢TGCT因局部复发的再次手术率为9%,弥漫性TGCT为23%。解读——这项首次全国性研究及对TGCT发病率的详细分析估计,全球手指、局限性四肢和弥漫型TGCT的发病率分别为每百万人年29例、10例和4例。弥漫型的复发率比局限性四肢高2.6倍。TGCT仍被认为是一种罕见疾病;然而,它比之前认为的更为常见。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b299/5694816/583f5210f297/iort-88-688.F07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b299/5694816/d41ae66c3943/iort-88-688.F01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b299/5694816/3b88fd5a2dd4/iort-88-688.F02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b299/5694816/12cc47e91d34/iort-88-688.F03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b299/5694816/feb227c13fa4/iort-88-688.F04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b299/5694816/dd544a24c332/iort-88-688.F05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b299/5694816/1bba53515f64/iort-88-688.F06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b299/5694816/583f5210f297/iort-88-688.F07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b299/5694816/d41ae66c3943/iort-88-688.F01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b299/5694816/3b88fd5a2dd4/iort-88-688.F02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b299/5694816/12cc47e91d34/iort-88-688.F03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b299/5694816/feb227c13fa4/iort-88-688.F04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b299/5694816/dd544a24c332/iort-88-688.F05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b299/5694816/1bba53515f64/iort-88-688.F06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b299/5694816/583f5210f297/iort-88-688.F07.jpg

相似文献

1
Higher incidence rates than previously known in tenosynovial giant cell tumors.腱鞘巨细胞瘤的发病率高于此前所知。
Acta Orthop. 2017 Dec;88(6):688-694. doi: 10.1080/17453674.2017.1361126. Epub 2017 Aug 8.
2
Tenosynovial Giant Cell Tumors in Children: A Similar Entity Compared With Adults.儿童腱鞘巨细胞瘤:与成人相似的实体。
Clin Orthop Relat Res. 2018 Sep;476(9):1803-1812. doi: 10.1007/s11999.0000000000000102.
3
Tenosynovial Giant Cell Tumor: Incidence, Prevalence, Patient Characteristics, and Recurrence. A Registry-based Cohort Study in Denmark.腱鞘巨细胞瘤:发病率、患病率、患者特征和复发。丹麦基于登记的队列研究。
J Rheumatol. 2017 Oct;44(10):1476-1483. doi: 10.3899/jrheum.160816. Epub 2017 Aug 1.
4
The Patient Perspective on the Impact of Tenosynovial Giant Cell Tumors on Daily Living: Crowdsourcing Study on Physical Function and Quality of Life.患者对腱鞘巨细胞瘤对日常生活影响的看法:关于身体功能和生活质量的众包研究
Interact J Med Res. 2018 Feb 23;7(1):e4. doi: 10.2196/ijmr.9325.
5
Effectiveness of arthroscopic excision based on the distribution of the tenosynovial giant cell tumor around knee joint.基于膝关节周围腱鞘巨细胞瘤分布的关节镜下切除术的疗效。
Knee. 2023 Mar;41:360-372. doi: 10.1016/j.knee.2023.01.024. Epub 2023 Feb 26.
6
The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study.弥漫型腱鞘巨细胞瘤(dt-TGCT)患者的诊治历程:一项前瞻性多中心研究。
Orphanet J Rare Dis. 2021 Apr 29;16(1):191. doi: 10.1186/s13023-021-01820-6.
7
Prognosis of Advanced Tenosynovial Giant Cell Tumor of the Knee Diagnosed During Total Knee Arthroplasty.全膝关节置换术中诊断出的晚期膝关节腱鞘巨细胞瘤的预后
J Arthroplasty. 2017 Jun;32(6):1850-1855. doi: 10.1016/j.arth.2016.12.053. Epub 2017 Jan 11.
8
Arthroscopic Excision of a Localized Tenosynovial Giant Cell Tumor of the Knee: A Case Report.关节镜下切除膝关节局限性腱鞘巨细胞瘤 1 例报告
Curr Rheumatol Rev. 2024;20(4):459-464. doi: 10.2174/0115733971272967231120114621.
9
Severity classification of Tenosynovial Giant Cell Tumours on MR imaging.腱鞘巨细胞瘤在磁共振成像上的严重程度分类
Surg Oncol. 2018 Sep;27(3):544-550. doi: 10.1016/j.suronc.2018.07.002. Epub 2018 Jul 3.
10
Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy.六例恶性腱鞘巨细胞瘤的临床特征和治疗结果:分子靶向治疗的初步经验。
BMC Cancer. 2018 Dec 29;18(1):1296. doi: 10.1186/s12885-018-5188-6.

引用本文的文献

1
Adverse events of pexidartinib for the treatment of TGCT: a real-world disproportionality analysis using FDA Adverse Event Reporting System database.培西达替尼治疗睾丸生殖细胞瘤的不良事件:使用美国食品药品监督管理局不良事件报告系统数据库进行的真实世界不成比例性分析。
Front Oncol. 2025 Aug 18;15:1594585. doi: 10.3389/fonc.2025.1594585. eCollection 2025.
2
Tenosynovial giant cell tumor and its differential diagnosis in children.儿童腱鞘巨细胞瘤及其鉴别诊断
Pediatr Radiol. 2025 Jul 19. doi: 10.1007/s00247-025-06338-8.
3
Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study.

本文引用的文献

1
Pigmented Villonodular Synovitis: A Comprehensive Review and Proposed Treatment Algorithm.色素沉着绒毛结节性滑膜炎:全面综述及建议的治疗方案
JBJS Rev. 2016 Jul 19;4(7). doi: 10.2106/JBJS.RVW.15.00086.
2
The effect of surgical synovectomy and radiotherapy on the rate of recurrence of pigmented villonodular synovitis of the knee: an individual patient meta-analysis.手术滑膜切除术和放射治疗对膝关节色素沉着绒毛结节性滑膜炎复发率的影响:一项个体患者荟萃分析。
Bone Joint J. 2015 Apr;97-B(4):550-7. doi: 10.1302/0301-620X.97B4.34907.
3
Functional outcome and quality of life after the surgical treatment for diffuse-type giant-cell tumour around the knee: a retrospective analysis of 30 patients.
培西达替尼治疗腱鞘巨细胞瘤患者的长期疗效和安全性:ENLIVEN研究的最终结果
Oncologist. 2025 Jul 4;30(7). doi: 10.1093/oncolo/oyae345.
4
The economic and humanistic burden of tenosynovial giant cell tumor: a targeted literature review.腱鞘巨细胞瘤的经济和人文负担:一项针对性文献综述
Future Oncol. 2025 Aug;21(18):2385-2400. doi: 10.1080/14796694.2025.2520744. Epub 2025 Jun 22.
5
Medical Management of Tenosynovial Giant Cell Tumor.腱鞘巨细胞瘤的医学管理
Curr Oncol Rep. 2025 May 20. doi: 10.1007/s11912-025-01679-x.
6
Tenosynovial Giant Cell Tumor Involving Quadriceps Muscle - A Case Report of Two Cases.累及股四头肌的腱鞘巨细胞瘤——两例病例报告
J Orthop Case Rep. 2025 Apr;15(4):192-198. doi: 10.13107/jocr.2025.v15.i04.5496.
7
Localized and diffuse tenosynovial giant cell tumor: real-world results from a patient observational registry.局限性和弥漫性腱鞘巨细胞瘤:来自患者观察性注册研究的真实世界结果。
Future Oncol. 2025 May;21(12):1501-1510. doi: 10.1080/14796694.2025.2488635. Epub 2025 Apr 8.
8
Patient-reported continued benefits of pexidartinib for tenosynovial giant cell tumor based on a real-world study in the United States.基于美国一项真实世界研究,患者报告培西达替尼对腱鞘巨细胞瘤持续有效。
Oncologist. 2025 Mar 10;30(3). doi: 10.1093/oncolo/oyaf028.
9
Intraarticular Involvement of Extraarticular Giant Cell Tumor of the Tendon Sheath in the Thumb of a Pediatric Patient: A Case Report.小儿患者拇指腱鞘外巨细胞瘤的关节内累及:一例报告
J Plast Reconstr Surg. 2024 Jul 5;4(1):46-49. doi: 10.53045/jprs.2024-0004. eCollection 2025 Jan 27.
10
Diffuse type tenosynovial giant cell tumour in the sinus tarsi in a paediatric patient: a rare case report with radiological and histopathological analysis.小儿患者跗骨窦弥漫型腱鞘巨细胞瘤:一例罕见病例报告及影像学和组织病理学分析
Skeletal Radiol. 2025 Aug;54(8):1773-1778. doi: 10.1007/s00256-025-04905-6. Epub 2025 Mar 13.
膝关节周围弥漫型巨细胞瘤手术治疗后的功能结果和生活质量:30 例回顾性分析。
Bone Joint J. 2014 Aug;96-B(8):1111-8. doi: 10.1302/0301-620X.96B8.33608.
4
Long-term follow-up results of primary and recurrent pigmented villonodular synovitis.原发性及复发性色素沉着绒毛结节性滑膜炎的长期随访结果
Rheumatology (Oxford). 2014 Nov;53(11):2063-70. doi: 10.1093/rheumatology/keu230. Epub 2014 Jun 10.
5
Pigmented villonodular synovitis: current concepts about diagnosis and management.色素沉着绒毛结节性滑膜炎:诊断与治疗的最新观念。
Future Oncol. 2013 Oct;9(10):1515-31. doi: 10.2217/fon.13.124.
6
Giant cell tumour of tendon sheath of the digits. A systematic review.手指腱鞘巨细胞瘤。一项系统评价。
Hand (N Y). 2011 Sep;6(3):244-9. doi: 10.1007/s11552-011-9341-9. Epub 2011 Jun 1.
7
A multidisciplinary approach to giant cell tumors of tendon sheath and synovium--a critical appraisal of literature and treatment proposal.多学科方法治疗腱鞘和滑膜巨细胞瘤——文献评价和治疗建议。
J Surg Oncol. 2013 Mar;107(4):433-45. doi: 10.1002/jso.23220. Epub 2012 Jul 17.
8
Long-term outcome of the treatment of high-risk tenosynovial giant cell tumor/pigmented villonodular synovitis with radiotherapy and surgery.放疗联合手术治疗高危腱鞘巨细胞瘤/色素绒毛结节性滑膜炎的长期疗效。
Cancer. 2012 Oct 1;118(19):4901-9. doi: 10.1002/cncr.26529. Epub 2012 Jan 26.
9
Pigmented villonodular synovitis: radiologic-pathologic correlation.色素沉着绒毛结节性滑膜炎:放射学与病理学相关性
Radiographics. 2008 Sep-Oct;28(5):1493-518. doi: 10.1148/rg.285085134.
10
Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive.荷兰的病理学数据库建设与生物样本库建设,PALGA发挥核心作用,PALGA是全国性的组织病理学和细胞病理学数据网络及档案库。
Cell Oncol. 2007;29(1):19-24. doi: 10.1155/2007/971816.